Vizuri Consumer launches topical analgesic for 24-hour arthritis relief
BALTIMORE — Vizuri Consumer Healthcare on Tuesday launched PainBloc24, a 24-hour over-the-counter topical pain reliever for arthritis joint pain. PainBloc24 has been clinically shown to help relieve pain with as little as one application per day, the company stated.
“This is a great milestone for our company, and we know the 53 million people who suffer from chronic arthritis pain need a longer-lasting pain reliever," stated Jeremy Puttock, VP Vizuri Consumer Healthcare. "We’re proud to bring a true breakthrough to the market and look forward to expanding distribution in the coming months.”
The patent-pending NeuroMax technology in PainBloc24 delivers the maximum allowable OTC dose of its pain-blocking medicine, capsaicin, to turn off certain nerve fibers that send pain signals to the brain. In a clinical study, 60% of patients reported a reduction in arthritic knee pain for 24 hours following one-to-two daily applications of PainBloc24. In addition, patients who used the product for just seven days continued to experience relief from their arthritis pain for an additional three weeks after the last application.
PainBloc24 is available exclusively online and will be rolled out to food, drug and mass retailers this summer.
ClearVia new probiotic supports better metabolization of alcohol
NEW YORK — ClearVia, a probiotic that naturally supports the body's ability to metabolize alcohol, launched nationwide on Wednesday. A proprietary probiotic blend, ClearVia helps the body's natural ability to break down alcohol while sleeping so after a night of enjoying a few drinks busy professionals can wake up clear and ready to take on their day, the company stated.
"We designed ClearVia for the social drinker who has lots of responsibilities balancing work and family and can't afford to miss a beat," stated Mauro Pennella, president ClearVia Labs. "It's a great aid for the professional who often socializes with clients as part of their work."
ClearVia specifically works by providing support to the liver so it can better metabolize alcohol. The probiotic blend helps turn acetaldehyde, that is formed when the body incompletely metabolizes alcohol, into mild acetic acid (vinegar). The more acetaldehyde build up someone has in their body the worse off they will feel in the morning.
The single-use, fast-dissolving orange flavored packets can be taken with water. According to a recent Gallup poll, nearly two thirds of Americans drink alcohol. Most Americans who drink alcohol do so regularly, as 67% reported having had at least one drink in the past week; 32% of Americans reported they had between one and seven drinks in the past week.
As people age, their body becomes less efficient at metabolizing alcohol. The activity of the enzymes necessary to process acetaldehyde decreases, which means it spends more time hanging out in the body causing unpleasant feelings in the morning.
ClearVia is currently available on Amazon and directly from ClearVia.com starting in May. It's available for a suggested retail price of $14.99 for five single packets or $24.99 for 10 single packets. In addition, ClearVia is also available to be purchased in bulk of 50 single serve packets.
2017 considered one of longest- and latest-running flu seasons
ATLANTA — The 2016/2017 influenza season is still ongoing. According to the latest statistics from the Centers for Disease Control and Prevention, flu incidence is still tracking above the national baseline, making this year both the longest-running season and the latest-running season in recent memory.
Last week the CDC reported a weighted national percentage of visits for influenza-like illnessess of 2.6%, still well above the 2.2% national baseline that indicates the beginning and end of a season. While this year started a little later than years past, it has already run a 17-week course and is still tracking. By comparison, the 2014/2015 season extended for approximately 16 weeks from start to finish.
Last year, ILI was above the 2.2% national baseline for only 11 weeks during the season, cresting at 3.6%. This year, ILI incidence reached a high mark of 5.1%.